HomeCompareGOVXW vs PEP

GOVXW vs PEP: Dividend Comparison 2026

GOVXW yields 57142.86% · PEP yields 3.66%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GOVXW wins by $1.8137199447430393e+24M in total portfolio value
10 years
GOVXW
GOVXW
● Live price
57142.86%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.8137199447430393e+24M
Annual income
$1,807,497,607,342,771,000,000,000,000,000.00
Full GOVXW calculator →
PEP
PepsiCo Inc.
● Live price
3.66%
Share price
$155.29
Annual div
$5.69
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$144.7K
Annual income
$63,430.49
Full PEP calculator →

Portfolio growth — GOVXW vs PEP

📍 GOVXW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGOVXWPEP
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GOVXW + PEP cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GOVXW pays
PEP pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GOVXW
Annual income on $10K today (after 15% tax)
$4,857,142.86/yr
After 10yr DRIP, annual income (after tax)
$1,536,372,966,241,355,200,000,000,000,000.00/yr
PEP
Annual income on $10K today (after 15% tax)
$311.45/yr
After 10yr DRIP, annual income (after tax)
$53,915.92/yr
At 15% tax rate, GOVXW beats the other by $1,536,372,966,241,355,200,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GOVXW + PEP for your $10,000?

GOVXW: 50%PEP: 50%
100% PEP50/50100% GOVXW
Portfolio after 10yr
$9.068599723715196e+23M
Annual income
$903,748,803,671,385,500,000,000,000,000.00/yr
Blended yield
99.66%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PEP right now

GOVXW
No analyst data
Altman Z
-40.6
Piotroski
1/9
PEP
Analyst Ratings
1
Strong
15
Buy
28
Hold
1
Sell
Consensus: Hold
Price Target
$172.43
+11.0% upside vs current
Range: $156.00 — $191.00
Altman Z
3.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GOVXW buys
0
PEP buys
6
PoliticianChamberTickerTypeAmountDate
Sheldon Whitehouse🏛 Senate$PEP▼ Sell$1,001 - $15,0002026-02-23
Sheldon Whitehouse🏛 Senate$PEP▼ Sell$1,001 - $15,0002026-02-23
Julia Letlow🏢 House$PEP▲ Buy$1,001 - $15,0002026-02-05
Julie Johnson🏢 House$PEP▼ Sell$1,001 - $15,0002025-12-18
Jared Moskowitz🏢 House$PEP▼ Sell$1,001 - $15,0002025-12-02
Jared Moskowitz🏢 House$PEP▼ Sell$1,001 - $15,0002025-12-02
Jared Moskowitz🏢 House$PEP▼ Sell$15,001 - $50,0002025-12-02
Julie Johnson🏢 House$PEP▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$PEP▲ Buy$1,001 - $15,0002025-11-05
Scott DesJarlais🏢 House$PEP▼ Sell$1,001 - $15,0002025-10-28
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGOVXWPEP
Forward yield57142.86%3.66%
Annual dividend / share$2.00$5.69
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$1.8137199447430393e+24M$144.7K
Annual income after 10y$1,807,497,607,342,771,000,000,000,000,000.00$63,430.49
Total dividends collected$1.813311652454266e+24M$125.7K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: GOVXW vs PEP ($10,000, DRIP)

YearGOVXW PortfolioGOVXW Income/yrPEP PortfolioPEP Income/yrGap
1← crossover$5,724,986$5,714,285.71$10,854$514.44+$5.71MGOVXW
2$3,063,527,985$3,057,402,250.62$11,982$758.21+$3063.52MGOVXW
3$1,532,308,824,967$1,529,030,850,022.66$13,526$1,136.44+$1532308.81MGOVXW
4$716,394,107,906,517$714,754,537,463,802.60$15,727$1,741.93+$716394107.89MGOVXW
5$313,071,475,901,711,400$312,304,934,206,251,460.00$19,012$2,750.28+$313071475901.69MGOVXW
6$127,886,778,198,343,160,000$127,551,791,719,128,320,000.00$24,173$4,514.44+$127886778198343.14MGOVXW
7$48,831,901,813,479,680,000,000$48,695,062,960,807,450,000,000.00$32,789$7,793.80+$48831901813479680.00MGOVXW
8$17,429,423,992,127,943,000,000,000$17,377,173,857,187,520,000,000,000.00$48,258$14,354.51+$17429423992127942656.00MGOVXW
9$5,815,268,598,381,736,000,000,000,000$5,796,619,114,710,159,000,000,000,000.00$78,586$28,686.63+$5.815268598381735e+21MGOVXW
10$1,813,719,944,743,039,200,000,000,000,000$1,807,497,607,342,771,000,000,000,000,000.00$144,688$63,430.49+$1.8137199447430393e+24MGOVXW

GOVXW vs PEP: Complete Analysis 2026

GOVXWStock

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is also developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. GeoVax Labs, Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

Full GOVXW Calculator →

PEPConsumer Staples

PepsiCo, Inc. manufactures, markets, distributes, and sells various beverages and convenient foods worldwide. The company operates through seven segments: Frito-Lay North America; Quaker Foods North America; PepsiCo Beverages North America; Latin America; Europe; Africa, Middle East and South Asia; and Asia Pacific, Australia and New Zealand and China Region. It provides dips, cheese-flavored snacks, and spreads, as well as corn, potato, and tortilla chips; cereals, rice, pasta, mixes and syrups, granola bars, grits, oatmeal, rice cakes, simply granola, and side dishes; beverage concentrates, fountain syrups, and finished goods; ready-to-drink tea, coffee, and juices; dairy products; and sparkling water makers and related products. It serves wholesale and other distributors, foodservice customers, grocery stores, drug stores, convenience stores, discount/dollar stores, mass merchandisers, membership stores, hard discounters, e-commerce retailers and authorized independent bottlers, and others through a network of direct-store-delivery, customer warehouse, and distributor networks, as well as directly to consumers through e-commerce platforms and retailers. The company was founded in 1898 and is headquartered in Purchase, New York.

Full PEP Calculator →
📬

Get this GOVXW vs PEP comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GOVXW vs SCHDGOVXW vs JEPIGOVXW vs OGOVXW vs KOGOVXW vs MAINGOVXW vs MOGOVXW vs PMGOVXW vs GIS

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.